Literature DB >> 22807381

Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.

Stewart M Knoepp1, Lakshmi P Kunju, Michael H Roh.   

Abstract

The diagnosis of metastatic renal cell carcinoma (RCC) in cytology specimens may be difficult to confirm on the basis of cytomorphology alone. Often, immunohistochemistry serves as an important adjunct in confirming this diagnosis. Recently, PAX2 was shown to be useful in this regard. In this study, we sought to compare the utility of PAX8 to that of PAX2 immunohistochemistry in the diagnosis of RCC in cytology specimens. First, we verified the performance of PAX8 immunohistochemistry on a tissue microarray (TMA) composed of 54 cases of RCC; PAX8 immunoreactivity was seen in at least 10% of the tumor cells in all cases. Next, we applied PAX8 immunohistochemistry to cell block sections prepared from 24 cases of RCC, obtained from fine-needle aspirates and effusion specimens. PAX2 immunohistochemistry was performed for comparison. Immunopositivity was defined as the presence of nuclear staining in at least 10% of tumor cell nuclei. Immunoreactivity for PAX8 and PAX2 was seen in 21 (88%) and 20 (83%) of the 24 cases, respectively. The presence of either PAX8 or PAX2 immunostaining was present in 22 of 24 cases, thus showing a total sensitivity of 92%. Overall, the results indicate that PAX8 and PAX2 are diagnostically useful adjuncts in confirming the diagnosis of RCC in cytology specimens.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22807381     DOI: 10.1002/dc.21590

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  9 in total

1.  PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Authors:  Meaghan L Barr; Lucia B Jilaveanu; Robert L Camp; Adebowale J Adeniran; Harriet M Kluger; Brian Shuch
Journal:  J Clin Pathol       Date:  2014-10-14       Impact factor: 3.411

2.  The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.

Authors:  Nehad M R Abd El-Maqsoud; Ehab Rifat Tawfiek; Ayman Abdelmeged; Mohamed Fathy Abdel Rahman; Alaa A E Moustafa
Journal:  Tumour Biol       Date:  2015-10-01

Review 3.  Immunocytochemistry of effusions: Processing and commonly used immunomarkers.

Authors:  Vinod B Shidham; Beata Janikowski
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

4.  PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.

Authors:  Yue Wang; Yiying Wang; Jie Li; Zeng Yuan; Bingbing Yuan; Tingguo Zhang; Janiel M Cragun; Beihua Kong; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

5.  DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer.

Authors:  Nan Jia; Jieyu Wang; Qing Li; Xiang Tao; Kaikai Chang; Keqin Hua; Yinhua Yu; Kwong-Kwok Wong; Weiwei Feng
Journal:  Oncotarget       Date:  2016-12-20

6.  CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis.

Authors:  Paola Ortiz-Montero; Win-Yan Liu-Bordes; Arturo Londoño-Vallejo; Jean-Paul Vernot
Journal:  Cancer Manag Res       Date:  2018-11-16       Impact factor: 3.989

7.  Expression of PAX2 and PAX8 in Wilms Tumor: A Tissue Microarray-based Immunohistochemical Study.

Authors:  Salma Sefidbakht; Atieh Khorsand; Sahar Omidi; Sedigheh Mohsenpourian; Elham Mirzaian
Journal:  Iran J Pathol       Date:  2021-05-09

8.  PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas.

Authors:  Li Xiang; Beihua Kong
Journal:  Oncol Lett       Date:  2013-01-10       Impact factor: 2.967

Review 9.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.